Literature DB >> 30287432

An update on the use of inhaled therapy in COPD.

Oliver Price1, Chandra Sarkar2, Shruthi Konda3.   

Abstract

Inhaled corticosteroids represent the mainstay of pharmacological treatment for reversible airways disease, and traditionally have had widespread use in non-reversible chronic obstructive pulmonary disease (COPD). However, use in this group may expose patients to an increased risk of pneumonia, without significant benefit to symptoms or exacerbation frequency. Here we provide a guide to the use of inhaled therapy in COPD for the general physician. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  COPD; inhaled corticosteroids

Mesh:

Substances:

Year:  2018        PMID: 30287432      PMCID: PMC6334108          DOI: 10.7861/clinmedicine.18-5-387

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  16 in total

1.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.

Authors:  Steven Pascoe; Nicholas Locantore; Mark T Dransfield; Neil C Barnes; Ian D Pavord
Journal:  Lancet Respir Med       Date:  2015-04-12       Impact factor: 30.700

2.  Withdrawal of inhaled corticosteroids in COPD: A meta-analysis.

Authors:  Luigino Calzetta; Maria Gabriella Matera; Fulvio Braido; Marco Contoli; Angelo Corsico; Fabiano Di Marco; Pierachille Santus; Nicola Scichilone; Mario Cazzola; Paola Rogliani
Journal:  Pulm Pharmacol Ther       Date:  2017-06-09       Impact factor: 3.410

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Authors:  Claus Vogelmeier; Bettina Hederer; Thomas Glaab; Hendrik Schmidt; Maureen P M H Rutten-van Mölken; Kai M Beeh; Klaus F Rabe; Leonardo M Fabbri
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.

Authors:  Henrik Watz; Kay Tetzlaff; Emiel F M Wouters; Anne Kirsten; Helgo Magnussen; Roberto Rodriguez-Roisin; Claus Vogelmeier; Leonardo M Fabbri; Pascal Chanez; Ronald Dahl; Bernd Disse; Helen Finnigan; Peter M A Calverley
Journal:  Lancet Respir Med       Date:  2016-04-07       Impact factor: 30.700

6.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Authors:  Helgo Magnussen; Bernd Disse; Roberto Rodriguez-Roisin; Anne Kirsten; Henrik Watz; Kay Tetzlaff; Lesley Towse; Helen Finnigan; Ronald Dahl; Marc Decramer; Pascal Chanez; Emiel F M Wouters; Peter M A Calverley
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

Review 7.  Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.

Authors:  Kayleigh M Kew; Alieksei Seniukovich
Journal:  Cochrane Database Syst Rev       Date:  2014-03-10

Review 8.  Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology.

Authors:  Nighat J Nadeem; Stephanie J C Taylor; Sandra M Eldridge
Journal:  Respir Res       Date:  2011-08-12

Review 9.  LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Authors:  Gustavo J Rodrigo; David Price; Antonio Anzueto; Dave Singh; Pablo Altman; Giovanni Bader; Francesco Patalano; Robert Fogel; Konstantinos Kostikas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-17

10.  Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Authors:  Claus F Vogelmeier; Mina Gaga; Maryam Aalamian-Mattheis; Timm Greulich; Jose M Marin; Walter Castellani; Vincent Ninane; Stephen Lane; Xavier Nunez; Francesco Patalano; Andreas Clemens; Konstantinos Kostikas
Journal:  Respir Res       Date:  2017-07-18
View more
  2 in total

1.  The challenge of change: evidence, culture and expertise.

Authors:  Ed Nicol
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

2.  Design, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs.

Authors:  Jack Ayre; Joanna M Redmond; Giovanni Vitulli; Laura Tomlinson; Richard Weaver; Eleonora Comeo; Cynthia Bosquillon; Michael J Stocks
Journal:  J Med Chem       Date:  2022-07-07       Impact factor: 8.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.